SCHEMBL2702188

SCHEMBL2702188

CN(C)S(=O)(=O)N1CCC(CN)(c2ccccc2)CC1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.53
MAOB P27338 1/20 0.53
TAAR1 Q96RJ0 1/20 0.53
DPP4 P27487 2/20 0.50
ALDH1A1 P00352 4/20 0.48
SMN1; SMN2 Q16637 3/20 0.46
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
GAA P10253 1/20 0.41
KDM4E B2RXH2 1/20 0.41
TSHR P16473 1/20 0.41
SLC6A2 P23975 1/20 0.41
SLC6A4 P31645 1/20 0.41
SLC6A3 Q01959 1/20 0.41
LMNA P02545 1/20 0.41
SLC6A9 P48067 1/20 0.39
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2701835 0.83 MAOA (0.61) MAOAMAOBTAAR1DPP4KMT2A
SCHEMBL2702237 0.81 SLC6A3 (0.48) DPP4MEN1KMT2AGAAKDM4E
SCHEMBL2701661 0.80 MAOA (0.53) MAOAMAOBTAAR1DPP4SMN1; SMN2
SCHEMBL4003496 0.79 SLC6A9 (0.55) MAOAMAOBTAAR1DPP4ALDH1A1
SCHEMBL2702185 0.77 SMN1; SMN2 (0.56) ALDH1A1SMN1; SMN2MEN1KMT2AL3MBTL1
SCHEMBL2700044 0.77 MAOA (0.49) MAOAMAOBTAAR1DPP4SMN1; SMN2
SCHEMBL468959 0.75 MAOA (0.68) MAOAMAOBTAAR1DPP4KMT2A
SCHEMBL2701822 0.74 PKM (0.60) MAOAMAOBTAAR1DPP4ALDH1A1
SCHEMBL2471293 0.74 SLC6A9 (0.56) ALDH1A1MEN1KMT2ALMNASLC6A9
Hydrochloric Acid SCHEMBL3597198 0.73 MAOA (0.66) MAOAMAOBTAAR1DPP4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2228065-B1 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB CO (US) 2012-12-26 EP disclosed
EP-1501467-B1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL MYERS SQUIBB CO (US) 2012-05-09 EP disclosed
EP-2228065-A2 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2010-09-15 EP disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 US disclosed
US-7005436-B2 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB COMPANY (US) 2006-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNH2, KCNQ5 MAOA 2507/4885MAOB 2828/4885TAAR1 2450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.